Literature DB >> 10471069

Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene: lack of a polymorphism in CYP1A2 in Caucasians.

M R Welfare1, M Aitkin, M F Bassendine, A K Daly.   

Abstract

The cytochrome P450 CYP1A2 is important in the metabolism of both drugs and procarcinogens such as heterocyclic amines. We aimed to clarify the existence of a phenotypic polymorphism and explore the molecular basis of such a polymorphism. Ninety-two non-smoking individuals underwent caffeine phenotyping. The distribution of the 1,7-dimethylxanthine + 1,7-dimethyluracil/caffeine (17U + 17X/137X) ratio and log-transformed data were determined. Probit plots were constructed and the distribution fitted using maximum likelihood method. The CYP1A2 gene, including upstream regulatory regions, was examined for sequence polymorphisms using the single-strand conformation polymorphism technique in 19 individuals and by complete DNA sequencing in two individuals from the extremes of the distribution. We found a similar range (1.45-18.65) and median (6.7) for the 17U + 17X/137X ratio to that found in previous studies of non-smoking Caucasians and no effect of sex. The 17U + 17X/137X ratio gave a normal distribution when log-transformed. Maximum likelihood analysis showed that the log-normal and bimodal distributions had similar deviances but the log-normal distribution was favoured because it has fewer parameters. There was no evidence for significant DNA sequence differences between fast and slow metabolizers, although some differences from published sequences including a silent polymorhpism in exon 7 which were unlikely to be of functional significance were found. We therefore conclude that CYP1A2 does not show functionally significant polymorphism but that the wide interindividual variation in activity may be due to environmental factors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10471069     DOI: 10.1097/00008571-199906000-00012

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  12 in total

Review 1.  Pharmacogenetics of asthma.

Authors:  A Fenech; Ian P Hall
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

2.  Determination of -3858G-->A and -164C-->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G-->A mutation between Caucasians and Asians.

Authors:  Liliane Todesco; Michael Török; Stephan Krähenbühl; Markus Wenk
Journal:  Eur J Clin Pharmacol       Date:  2003-07-08       Impact factor: 2.953

3.  Population pharmacokinetics of clozapine and its primary metabolite norclozapine in Chinese patients with schizophrenia.

Authors:  Li-jun Li; De-wei Shang; Wen-biao Li; Wei Guo; Xi-pei Wang; Yu-peng Ren; An-ning Li; Pei-xin Fu; Shuang-min Ji; Wei Lu; Chuan-yue Wang
Journal:  Acta Pharmacol Sin       Date:  2012-07-23       Impact factor: 6.150

4.  The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects.

Authors:  M R Welfare; M F Bassendine; A K Daly
Journal:  Br J Clin Pharmacol       Date:  2000-03       Impact factor: 4.335

5.  Phenotypic polymorphism and gender-related differences of CYP1A2 activity in a Chinese population.

Authors:  D S Ou-Yang; S L Huang; W Wang; H G Xie; Z H Xu; Y Shu; H H Zhou
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 6.  Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.

Authors:  Sean C Gay; Arthur G Roberts; James R Halpert
Journal:  Future Med Chem       Date:  2010-09       Impact factor: 3.808

7.  Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy.

Authors:  Keiji Takata; Junji Saruwatari; Naoyuki Nakada; Mizuna Nakagawa; Koichiro Fukuda; Fujiho Tanaka; Shinobu Takenaka; Shuichi Mihara; Toru Marubayashi; Kazuko Nakagawa
Journal:  Eur J Clin Pharmacol       Date:  2005-12-30       Impact factor: 2.953

8.  Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.

Authors:  Christoph Sachse; Upinder Bhambra; Gillian Smith; Tracy J Lightfoot; Jennifer H Barrett; Jenna Scollay; R Colin Garner; Alan R Boobis; C Roland Wolf; Nigel J Gooderham
Journal:  Br J Clin Pharmacol       Date:  2003-01       Impact factor: 4.335

9.  Identification of a novel splice-site mutation in the CYP1A2 gene.

Authors:  Delphine Allorge; Dany Chevalier; Jean-Marc Lo-Guidice; Christelle Cauffiez; Françoise Suard; Pierre Baumann; Chin B Eap; Franck Broly
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

10.  Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers.

Authors:  Joshua E Muscat; Brian Pittman; Wayne Kleinman; Philip Lazarus; Steven D Stellman; John P Richie
Journal:  Biochem Pharmacol       Date:  2008-07-25       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.